Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Yttrium Y-90 clivatuzumab tetraxetan |
Synonyms | |
Therapy Description |
Yttrium Y-90 clivatuzumab tetraxetan (IMMU-107) consists of an anti-MUC1 antibody conjugated to radioactive yttrium Y 90, which binds and delivers cytotoxic radiation to MUC1-expressing tumor cells (PMID: 26187510). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Yttrium Y-90 clivatuzumab tetraxetan | IMMU-107|90Y-hPAM4 | Yttrium Y-90 clivatuzumab tetraxetan (IMMU-107) consists of an anti-MUC1 antibody conjugated to radioactive yttrium Y 90, which binds and delivers cytotoxic radiation to MUC1-expressing tumor cells (PMID: 26187510). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01956812 | Phase III | Yttrium Y-90 clivatuzumab tetraxetan Gemcitabine | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1) | Terminated | USA | POL | ISR | FRA | ESP | CAN | BEL | AUT | 0 |